Back to Search Start Over

High-Dose Oral Posaconazole for the Treatment of Recalcitrant Fungal Keratitis.

Authors :
Ferguson TJ
Downes RA
Isada CM
Goshe JM
Source :
Cornea [Cornea] 2022 Jul 01; Vol. 41 (7), pp. 852-856. Date of Electronic Publication: 2021 Aug 30.
Publication Year :
2022

Abstract

Purpose: To report the successful treatment of 3 cases of recalcitrant fungal keratitis (FK) with high-dose oral posaconazole.<br />Methods: This is a series of 3 patients from a single academic center with a culture-positive FK who were treated with oral posaconazole after failing to respond to conventional treatments.<br />Results: All 3 patients had a history of contact lens wear. Two of the 3 cases were culture positive for Fusarium and the other for Paecilomyces . The infections of all 3 failed to respond to conventional antifungal therapies including varying combinations of topical, systemic, and intraocular antifungal therapies. All 3 cases rapidly responded to high-dose oral posaconazole ranging from 500 to 600 mg once daily. In 1 case, multiple courses of high-dose therapy were required to treat delayed recurrences of a latent infection. There were no significant adverse effects with the elevated dose, and treatment was administered with the guidance of an infectious disease specialist.<br />Conclusions: In cases of recalcitrant FK failing to respond to conventional therapies, high-dose posaconazole, in the delayed-release tablet formulation, can be an effective treatment option.<br />Competing Interests: The authors have no funding or conflicts of interest to disclose.<br /> (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1536-4798
Volume :
41
Issue :
7
Database :
MEDLINE
Journal :
Cornea
Publication Type :
Academic Journal
Accession number :
34469337
Full Text :
https://doi.org/10.1097/ICO.0000000000002832